At AAPS PharmSci 360 2025, held from Nov. 9–12 in San Antonio, Texas, Corey Bloom, PhD, associate director, CMC (chemistry, manufacturing, and controls) and Bioavailability Enhancement at Lonza, gave ...

The FDA's CNPV program accelerates product reviews to two months for national priority products, enhancing market entry speed. Vouchers are awarded for commitments to affordability, domestic ...

Robust scale-down agitation models simulate mechanical stress essential for assessing and preventing protein aggregation in high-concentration biologics. For early-stage testing, an orbital shaker ...

To prevent catastrophic loss of expertise and investment, government and academic leaders say coordinated policy and significant investment in workforce talent are urgently needed in the UK.

A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

A streamlined workflow using Six Sigma's DMAIC methodology was developed to identify and mitigate visible particles in biologics, reducing time and resources while maintaining quality.

To learn more about how method validation is performed for biomarker bioanalysis, Pharmaceutical Technology ® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, as ...

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and the overall experience of attending the CPHI conference.

Steve will be monitoring the Rapid Fires: AI/ML in Bioanalysis session on Monday, Nov. 10, 2025 at 3PM CT at AAPS PharmSci 360 2025, being held Nov. 9–12 in San Antonio, Texas. Click the video above ...

In the life sciences industry, the journey from discovery to delivery is only as strong as the supply chain and distribution network behind it. As the industry continues to evolve—driven by advanced ...

Tariffs increase operational costs by raising prices for raw materials, APIs, and finished drugs, complicating logistics and straining inventories. Companies are reshoring manufacturing to avoid ...